INNO-105 in Patients With Solid Tumors
Phase 1
Terminated
- Conditions
- Tumors
- First Posted Date
- 2005-11-18
- Last Posted Date
- 2007-05-14
- Lead Sponsor
- Innovive Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT00255333
- Locations
- 🇺🇸
Mary Crowley Medical Research Center, Dallas, Texas, United States
🇺🇸University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath